Frequent ERBB4 mutations in melanoma
Nature Genetics
August 31, 2009
Mutations in the gene ERBB4 were found in 19% of metatstatic melanomas, a skin cancer that is often fatal, according to a study published online in this week's Nature Genetics. While early-stage melanoma is often cured by surgery, metastatic melanoma is difficult to treat and is almost always fatal.
Since the protein tyrosine kinase (PTK) genes are frequently mutated in cancer, Yardena Samuels and colleagues sequenced 86 PTK genes in 29 melanomas and found 30 tumor-specific mutations in 19 of the 86 PTK genes. Additional sequencing in 79 more melanoma tumors identified 99 cancer-specific mutations, 19% of which were mutations occurring in the PTK gene ERBB4.
Further experiments showed that the mutations in ERBB4 increased growth of melanoma cells in the lab, but treatment of cells with the pharmacological inhibitor lapitinib reduced melanoma cell growth. The research suggests that targeting ERBB4 with small-molecule inhibitors should be investigated as a therapeutic approach for those with melanomas carrying mutations in this gene.
doi: 10.1038/ng.438
Research highlights
-
Aug 5
Microbiology: Single switch makes Escherichia coli beneficial insect partnerNature Microbiology
-
Aug 5
Conservation: More than half of unassessable species may be at risk of extinctionCommunications Biology
-
Aug 4
Physiology: Restoring cellular functions in pigs after deathNature
-
Aug 3
Zoology: Mother’s iron helps Weddell seal pups diveNature Communications
-
Aug 2
Health: Certain medications may impact risk of heat-related heart attacksNature Cardiovascular Research
-
Jul 28
Archaeology: Ancient humans were consuming milk long before they could digest itNature